The Hepatitis C Scorecard: Gilead is Trouncing AbbVie, but at a Price

Most everyone likes to keep score of something. So for those of you who like to track the bruising battle between Gilead Sciences and AbbVie, we have a scorecard. And Gilead is coming out ahead.

Gilead has nailed contracts with Anthem, CVS Caremark, OptumRx, Catamaran, Cigna and Wellcare. These deals give its Harvoni and Sovaldi hepatitis C treatment either preferred or exclusive formulary status. As a result, it has a dominating market share over AbbVie.